The role of concomitant cardiovascular diseases and cardiac biomarkers for predicting mortality in critical COVID-19 patients

While the received traditional predictors are still the mainstay in the diagnosis and prognosis of CVD events, increasing studies have focused on exploring the ancillary effect of biomarkers for the aspiring of precision. Under which circumstances, soluble ST2 (sST2), lipoprotein-associated phospholipase A2 (Lp-PLA2), myeloperoxidase (MPO), and procalcitonin (PCT) have recently emerged as promising markers in the field of both acute and chronic cardiovascular diseases. Existent clinical studies have demonstrated the significant associations between these markers with various CVD outcomes, which further verified the potentiality of markers in helping risk stratification and diagnostic and therapeutic work-up of patients. The current review article is aimed at illuminating the applicability of these four novels and often neglected cardiac biomarkers in common clinical scenarios, including acute myocardial infarction, acute heart failure, and chronic heart failure, especially in the emergency department. By thorough classification, combination, and discussion of biomarkers with clinical and instrumental evaluation, we hope the current study can provide insights into biomarkers and draw more attention to their importance.

Download Full-text

The Role of sST-2 in Predicting Cardiovascular Diseases

Kardiologiia vid nauky do praktyky ◽

10.30702/card:sp.2019.05.036/0223853 ◽

2019 ◽

pp. 38-53

Author(s):

Ja. Hilova ◽

M. Kopytsya ◽

J. Rodionova

Keyword(s):

Cardiovascular Diseases

Download Full-text

Role of intestinal microbiota in cardiovascular diseases

Practical medicine ◽

10.32000/2072-1757-2020-1-54-59 ◽

2020 ◽

Vol 18 (1) ◽

pp. 54-59

Author(s):

R. A. FAYZULLINA ◽

◽

K. A. SAFINA ◽

Keyword(s):

Cardiovascular Diseases ◽

Intestinal Microbiota

Download Full-text

The Renin Angiotensin System and Bipolar Disorder: A Systematic Review

Protein and Peptide Letters ◽

10.2174/0929866527666200127115059 ◽

2020 ◽

Vol 27 (6) ◽

pp. 520-528 ◽

Cited By ~ 2

Author(s):

Izabela Guimarães Barbosa ◽

Giulia Campos Ferreira ◽

Diomildo Ferreira Andrade Júnior ◽

Cássio Rocha Januário ◽

André Rolim Belisário ◽

...

Keyword(s):

Systematic Review ◽

Bipolar Disorder ◽

Cardiovascular Diseases ◽

Renin Angiotensin System ◽

Plasma Renin ◽

Angiotensin Receptors ◽

Angiotensin System ◽

Renin Angiotensin ◽

Search Terms

Bipolar Disorder (BD) is a chronic a multifactorial psychiatric illness that affects mood, cognition, and functioning. BD is associated with several psychiatric conditions as well clinical comorbidities, particularly cardiovascular diseases. The neurobiology of BD is complex and multifactorial and several systems have been implicated. Considering that the Renin Angiotensin System (RAS) plays an important role in cardiovascular diseases and that recently evidence has suggested its role in psychiatric disorders, the aim of the present study is to summarize and to discuss recent findings related to the modulation of RAS components in BD. A systematic search of the literature using the electronic databases MEDLINE and LILACS was conducted through March 2019. The search terms were: “Bipolar Disorder”; “Renin Angiotensin System”; “Angiotensin 2”; “Angiotensin receptors”; “Angiotensin 1-7”; “ACE”; “ACE2”; “Mas Receptor”. We included original studies assessing RAS in BD patients. Two hundred twenty-two citations were initially retrieved. Eleven studies were included in our systematic review. In the majority of studies (6 of 8), the ACE insertion/deletion (I/D) polymorphism did not differ between BD patients and controls. BD patients presented higher plasma renin activity in comparison with controls. The studies evaluating the RAS molecules in BD are very scarce and heterogeneous. The literature suggests a potential role of RAS in BD. Further studies are necessary to investigate this relationship.

Download Full-text

The Role of Statins in the Activation of Heme Oxygenase-1 in Cardiovascular Diseases

Current Drug Targets ◽

10.2174/1389450117666160401123600 ◽

2017 ◽

Vol 18 (6) ◽

pp. 674-686 ◽

Cited By ~ 8

Author(s):

Aleksandra Piechota-Polanczyk ◽

Alicja Jozkowicz

Keyword(s):

Cardiovascular Diseases ◽

Heme Oxygenase ◽

Heme Oxygenase 1

Download Full-text

Potential regulatory role of epigenetic RNA methylation in cardiovascular diseases

Biomedicine & Pharmacotherapy ◽

10.1016/j.biopha.2021.111376 ◽

2021 ◽

Vol 137 ◽

pp. 111376

Author(s):

Sumra Komal ◽

Li-Rong Zhang ◽

Sheng-Na Han

Keyword(s):

Cardiovascular Diseases ◽

Regulatory Role ◽

Rna Methylation ◽

Potential Regulatory Role

Download Full-text

Exploring the Potential Role of the Gut Microbiome in Chemotherapy-Induced Neurocognitive Disorders and Cardiovascular Toxicity

Cancers ◽

10.3390/cancers13040782 ◽

2021 ◽

Vol 13 (4) ◽

pp. 782

Author(s):

Sona Ciernikova ◽

Michal Mego ◽

Michal Chovanec

Keyword(s):

Cardiovascular Diseases ◽

Cancer Survivors ◽

Cancer Patients ◽

Gut Microbiome ◽

Late Effects ◽

Fecal Microbiota Transplantation ◽

Experimental Models ◽

Neurocognitive Disorders ◽

Cardiovascular Toxicity

Chemotherapy, targeting not only malignant but also healthy cells, causes many undesirable side effects in cancer patients. Due to this fact, long-term cancer survivors often suffer from late effects, including cognitive impairment and cardiovascular toxicity. Chemotherapy damages the intestinal mucosa and heavily disrupts the gut ecosystem, leading to gastrointestinal toxicity. Animal models and clinical studies have revealed the associations between intestinal dysbiosis and depression, anxiety, pain, impaired cognitive functions, and cardiovascular diseases. Recently, a possible link between chemotherapy-induced gut microbiota disruption and late effects in cancer survivors has been proposed. In this review, we summarize the current understanding of preclinical and clinical findings regarding the emerging role of the microbiome and the microbiota–gut–brain axis in chemotherapy-related late effects affecting the central nervous system (CNS) and heart functions. Importantly, we provide an overview of clinical trials evaluating the relationship between the gut microbiome and cancer survivorship. Moreover, the beneficial effects of probiotics in experimental models and non-cancer patients with neurocognitive disorders and cardiovascular diseases as well as several studies on microbiota modulations via probiotics or fecal microbiota transplantation in cancer patients are discussed.

Download Full-text

Regulation of miRNAs by Natural Antioxidants in Cardiovascular Diseases: Focus on SIRT1 and eNOS

Antioxidants ◽

10.3390/antiox10030377 ◽

2021 ◽

Vol 10 (3) ◽

pp. 377

Author(s):

Yunna Lee ◽

Eunok Im

Keyword(s):

Oxidative Stress ◽

Cardiovascular Diseases ◽

Endothelial Dysfunction ◽

Natural Antioxidants ◽

Sirtuin 1 ◽

Potential Benefits ◽

New Perspective ◽

Oxide Synthase ◽

Endothelial Nitric Oxide

Cardiovascular diseases (CVDs) are the most common cause of morbidity and mortality worldwide. The potential benefits of natural antioxidants derived from supplemental nutrients against CVDs are well known. Remarkably, natural antioxidants exert cardioprotective effects by reducing oxidative stress, increasing vasodilation, and normalizing endothelial dysfunction. Recently, considerable evidence has highlighted an important role played by the synergistic interaction between endothelial nitric oxide synthase (eNOS) and sirtuin 1 (SIRT1) in the maintenance of endothelial function. To provide a new perspective on the role of natural antioxidants against CVDs, we focused on microRNAs (miRNAs), which are important posttranscriptional modulators in human diseases. Several miRNAs are regulated via the consumption of natural antioxidants and are related to the regulation of oxidative stress by targeting eNOS and/or SIRT1. In this review, we have discussed the specific molecular regulation of eNOS/SIRT1-related endothelial dysfunction and its contribution to CVD pathologies; furthermore, we selected nine different miRNAs that target the expression of eNOS and SIRT1 in CVDs. Additionally, we have summarized the alteration of miRNA expression and regulation of activities of miRNA through natural antioxidant consumption.

Download Full-text

Osteopontin in Cardiovascular Diseases

Biomolecules ◽

10.3390/biom11071047 ◽

2021 ◽

Vol 11 (7) ◽

pp. 1047

Author(s):

Kohsuke Shirakawa ◽

Motoaki Sano

Keyword(s):

Cardiovascular Risk ◽

Cardiovascular Diseases ◽

Therapeutic Target ◽

Gene Mutations ◽

Major Adverse Cardiovascular Event ◽

Matricellular Protein ◽

Pathological State ◽

Adverse Cardiovascular Event ◽

Anti Inflammatory

Unprecedented advances in secondary prevention have greatly improved the prognosis of cardiovascular diseases (CVDs); however, CVDs remain a leading cause of death globally. These findings suggest the need to reconsider cardiovascular risk and optimal medical therapy. Numerous studies have shown that inflammation, pro-thrombotic factors, and gene mutations are focused not only on cardiovascular residual risk but also as the next therapeutic target for CVDs. Furthermore, recent clinical trials, such as the Canakinumab Anti-inflammatory Thrombosis Outcomes Study trial, showed the possibility of anti-inflammatory therapy for patients with CVDs. Osteopontin (OPN) is a matricellular protein that mediates diverse biological functions and is involved in a number of pathological states in CVDs. OPN has a two-faced phenotype that is dependent on the pathological state. Acute increases in OPN have protective roles, including wound healing, neovascularization, and amelioration of vascular calcification. By contrast, chronic increases in OPN predict poor prognosis of a major adverse cardiovascular event independent of conventional cardiovascular risk factors. Thus, OPN can be a therapeutic target for CVDs but is not clinically available. In this review, we discuss the role of OPN in the development of CVDs and its potential as a therapeutic target.

Download Full-text